Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND: AZD9550 + AZD6234 for Weight Loss in Obesity or Overweight
jRCT2051240287Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Modality
- Small Molecules, Peptides
01
Overview
Randomised, double-blind trial of AZD9550 and lenbelintide in obesity and Overweight (9 arms), sponsored by AstraZeneca. Primary endpoints: Percent change in body weight from baseline at 36 weeks and Proportion with ≥5% weight loss from baseline at 36 weeks. Started Apr 2025; status: active, not recruiting.
02
Drugs
AZD9550lenbelintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on jRCT2051240287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240287.